T-Cell Therapy (ECT204) in Adults With Advanced HCC

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC systemic agents.

Trial Details

NCT ID
NCT04864054
Phase
PHASE1 / PHASE2
Sponsor
Eureka Therapeutics Inc.
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • ECT204 T cells
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Westwood, Kansas, United States|39.04056,-94.6169
  • Buffalo, New York, United States|42.88645,-78.87837
  • Portland, Oregon, United States|45.52345,-122.67621
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Histologically confirmed HCC, that is unresectable, recurrent, and/or metastatic.
  • GPC3-positive tumor expression confirmed by immunohistochemistry (IHC).
  • For the dose-escalation cohort: ≥10-20% tumor cells, ≥2+ IHC.
  • Beginning with the RP2D confirmatory cohort: ≥ 50% tumor cells, 2+/3+ IHC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →